Meta AnalysisID 5644
中药注射剂治疗晚期非小细胞肺癌临床疗效与安全性的证据评价：随机对照试验的系统评价与Meta分析
CRD42023400730
To evaluate the effects and safety of Chinese herbal injections (including Aidi injection, Elemene injection, Kanglaite injection, Xiaiping injection, Compound Kushen injection, Shenqi Fuzheng injection) combined with ch
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 5644
- Evidence Id
- 14202
- Core Evidence Id
- 14202
- Source Meta Analysis Id
- 5627
- Herb2 Meta Analysis Id
- HBMA005627
- Crd Id
- CRD42023400730
- Title
- Evidence assessment for clinical efficacy and safety of Chinese herbal injections in treating advanced non–small-cell lung carcinoma: A systematic review and meta-analysis of randomized controlled trials
- Review Question
- To evaluate the effects and safety of Chinese herbal injections (including Aidi injection, Elemene injection, Kanglaite injection, Xiaiping injection, Compound Kushen injection, Shenqi Fuzheng injection) combined with chemotherapy on patients with advanced non–small-cell lung carcinoma (NSCLC).
- Study Type Included
- Only clinical randomized controlled trials (RCTs) will be included.
- Condition Being Studied
- It was estimated that lung cancer is the most common cancer and there were 1761007 deaths and 2093876 new cases in 2018 in the world. Most lung cancers (85%) belong to non-small cell lung cancer (NSCLC) that is the common subgroup. NSCLC accounts for approximately 85% of lung cancer casesand most NSCLC patients present with advanced-stage, unresectable disease.
- Participant
- Adults with cytological or pathological diagnosis of NSCLC.
- Animal
- Human Disease Modelled
- Intervention
- NSCLC patients in the experimental group were treated with one Chinese herbal injection (CHI), or the combination therapy of one CHI plus chemotherapy.
- Comparator Control
- NSCLC patients in the control group were treated with another CHI (other than the CHI in the experimental group), or the combination therapy of another CHI plus chemotherapy.
- Main Outcome
- The disease control rate(DCR), objective tumor response rate (ORR), survival rate, quality of life (QOL), improvement of Karnofsky performance score (KPS), the adverse side effects, and indicators of immune function were considered as outcome measures. Measures of effect Pooled odds ratio (OR) and 95% confidence interval (95% CI) will be used for statistical analysis of dichotomous variables while weighted mean difference (WMD) or standardized mean difference (SMD) and 95% CI will be used for continuous variables.
- Outcome Measure
- Additional Outcome
- None.
- Study Method
- Meta-analysis, Network meta-analysis, Systematic review
- Keyword
- Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; elemene; kang-lai-te; kushen; shenqi fuzheng
- Contact
- Yongliang Jia [email protected]
- Organisational Affiliation
- Zhengzhou University http://english.zzu.edu.cn/
- Funding Source
- Part of the work of Yongliang Jia was financially supported by the Henan Institute of Medical and Pharmacological Sciences (Grant No. 2021BP0113), the Zhengzhou University (Grant No. 32212456), and Henan Science and Technology Department (Grant No. 222102310721).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-02-18
- Registration Date
- 2023-02-28
- Anticipated Start Date
- 2023-02-20
- Anticipated Completion Date
- 2023-10-08
- Title Cn
- 中药注射剂治疗晚期非小细胞肺癌临床疗效与安全性的证据评价：随机对照试验的系统评价与Meta分析
- Title En
- Evidence assessment for clinical efficacy and safety of Chinese herbal injections in treating advanced non–small-cell lung carcinoma: A systematic review and meta-analysis of randomized controlled trials
- Bilingual Status
- complete